HER2-Low, HR-Positive, and Triple-Negative Breast Cancer: Expert Training and Real-world Perspectives on Novel HER2-Targeted and TROP-2–Targeted Therapies

This educational series will help healthcare professionals to effectively personalize the care of patients with breast cancer and will provide evidence-based expert perspectives on the implications of recent classification changes in HER2 expression levels, including discussions about TROP-2–targeted therapies for HER2-negative breast cancer with the aim to optimize treatment outcomes for patients with HER2-low, HR-positive, and triple-negative breast cancer. After the education, download the associated slidesets for use in the clinic.

Share

Program Content

Activities

HER2 Expression Spectrum: Module
Spectrum of HER2 Expression and Its Clinical Implications in Breast Cancer
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: January 08, 2024

Expires: January 07, 2025

HER2 Expression Spectrum: Slides
HER2 Expression in Breast Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 08, 2024

Activities

HER2 Low Advanced BC: Module
Pushing the Boundaries of Unresectable or Metastatic HER2-Low Breast Cancer Treatment: New Insights and Innovations
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: January 26, 2024

Expires: January 25, 2025

HER2 Low Advanced BC: Slides
Pushing the Boundaries of Unresectable or Metastatic HER2-Low Breast Cancer Treatment: New Insights and Innovations
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 26, 2024

Activities

Safety of ADCs in MBC: Module
Optimizing Outcomes and Quality of Life for Patients With Advanced Breast Cancer Through Effective Management of ADC-Associated Toxicities
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: February 07, 2024

Expires: February 06, 2025

Safety of ADCs in MBC: Slides
Optimizing Outcomes and Quality of Life for Patients With Advanced Breast Cancer Through Effective Management of ADC-Associated Toxicities
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 07, 2024

Activities

TROP2 Targeted Therapy: Module
TROP-2–Targeted Therapy: Redefining the Therapeutic Landscape in HER2-Negative Breast Cancer
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: February 22, 2024

Expires: February 21, 2025

TROP2 Targeted Therapy: Slides
TROP-2–Targeted Therapy: Redefining the Therapeutic Landscape in HER2-Negative Breast Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 22, 2024

Activities

Novel ADCs in Advanced Breast Cancer
Real-world Perspectives on Novel HER2-Targeted and TROP-2–Directed Therapies in Advanced Breast Cancer
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: March 20, 2024

Expires: March 19, 2025

Faculty

cover img faculity

Komal Jhaveri, MD, FACP

Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

cover img faculity

Melinda Telli, MD

Professor of Medicine
Stanford University School of Medicine
Director, Breast Cancer Program
Stanford Cancer Institute
Palo Alto, California

cover img faculity

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.